Journal article · 2026
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
New England Journal of Medicine · Published 25 October 2026 · DOI 10.1056/nejmoa2611280
In brief
“Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC” is a 2026 journal article by Fei Zhou and 38 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 2
- Most cited in
- 2026 (2)
- Field-weighted impact
- 4.80
- References
- 21
- Authors
- 39
Abstract
BACKGROUND: Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain suboptimal. METHODS: In this phase 3, open-label, randomized trial, we evaluated sacituzumab tirumotecan plus pembrolizumab in… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhou, F., Meng, X., Ding, Q., Zhang, P., Liang, W., Guo, S., Yu, Y., Yao, W., Fan, Y., Pu, X., Liu, C., Cui, J., Chen, P., Zhong, H., Wang, Y., Huang, Z., Xu, Z., Dong, X., Yi, T., . . . Zhou, C. (2026). Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280
MLA 9
Zhou, Fei, et al. “Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2611280.
Chicago
Zhou, Fei, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, et al. 2026. “Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280.
Harvard
Zhou, F. et al. (2026) ‘Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC’, New England Journal of Medicine. doi:10.1056/nejmoa2611280.
IEEE
F. Zhou et al., “Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2611280.
BibTeX
@article{zhou2026sacituzumab,
title = {{Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC}},
author = {Zhou, Fei and Meng, Xiangjiao and Ding, Qingqing and Zhang, Peng and Liang, Wenhua and Guo, Sanxing and Yu, Yan and Yao, Wenxiu and Fan, Yun and Pu, Xingxiang and Liu, Chunling and Cui, Jiuwei and Chen, Peng and Zhong, Hua and Wang, Yongsheng and Huang, Zhangzhou and Xu, Zhi and Dong, Xiaorong and Yi, Tienan and Hu, Ying and Wang, Qiming and Chen, Bolin and Wang, Hui and Sun, Longhua and He, Lang and Zheng, Wei and Wang, Yina and Zhang, Xiaochen and Yao, Yu and Li, Yongsheng and others},
journal = {New England Journal of Medicine},
year = {2026},
doi = {10.1056/nejmoa2611280},
url = {https://doi.org/10.1056/nejmoa2611280}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- sacituzumab tirumotecan
- pembrolizumab
- non-squamous non-small cell lung cancer
- first-line therapy
- immune checkpoint inhibitors
- chemotherapy
- progression-free survival
- overall survival
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zhou, F., Meng, X., Ding, Q., Zhang, P., Liang, W., Guo, S., Yu, Y., Yao, W., Fan, Y., Pu, X., Liu, C., Cui, J., Chen, P., Zhong, H., Wang, Y., Huang, Z., Xu, Z., Dong, X., Yi, T., . . . Zhou, C. (2026). Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280
How many times has this paper been cited?
2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui and 27 more.
What is the DOI of this paper?
10.1056/nejmoa2611280, permanently at https://doi.org/10.1056/nejmoa2611280. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.